Protalix Biotherapeutics Inc Net Assets
Protalix Biotherapeutics Inc net assets. Based on the latest financial reports, Protalix Biotherapeutics Inc (PLX) has net assets worth $48.23 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($82.35 Million) and total liabilities ($34.12 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore PLX net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $48.23 Million |
| % of Total Assets | 58.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 648.61 |
Net Assets of Protalix Biotherapeutics Inc (1996–2025)
Net assets of Protalix Biotherapeutics Inc from 1996 to 2025. This chart illustrates how Protalix Biotherapeutics Inc's net assets have evolved over time, based on quarterly financial data. See Protalix Biotherapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Protalix Biotherapeutics Inc (1996–2025)
The table below shows the annual net assets of Protalix Biotherapeutics Inc from 1996 to 2025. For live market cap and overall valuation, see market value of Protalix Biotherapeutics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $48.23 Million | +11.62% |
| 2024-12-31 | $43.21 Million | +28.72% |
| 2023-12-31 | $33.57 Million | +415.50% |
| 2022-12-31 | $-10.64 Million | -76.28% |
| 2021-12-31 | $-6.04 Million | +77.68% |
| 2020-12-31 | $-27.04 Million | +61.55% |
| 2019-12-31 | $-70.32 Million | -32.98% |
| 2018-12-31 | $-52.88 Million | -68.99% |
| 2017-12-31 | $-31.29 Million | -214.28% |
| 2016-12-31 | $-9.96 Million | -191.58% |
| 2015-12-31 | $10.87 Million | +119.56% |
| 2014-12-31 | $-55.60 Million | -106.34% |
| 2013-12-31 | $-26.95 Million | -702.68% |
| 2012-12-31 | $-3.36 Million | +87.13% |
| 2011-12-31 | $-26.08 Million | -130.30% |
| 2010-12-31 | $-11.32 Million | -171.29% |
| 2009-12-31 | $15.88 Million | -64.18% |
| 2008-12-31 | $44.35 Million | -30.37% |
| 2007-12-31 | $63.69 Million | +162.25% |
| 2006-12-31 | $24.28 Million | +2555.64% |
| 2005-12-31 | $914.43K | +84.60% |
| 2004-12-31 | $495.36K | -24.42% |
| 2003-12-31 | $655.43K | -17.67% |
| 2002-12-31 | $796.15K | -15.83% |
| 2001-12-31 | $945.91K | -29.61% |
| 2000-12-31 | $1.34 Million | -15.42% |
| 1999-12-31 | $1.59 Million | -52.64% |
| 1998-12-31 | $3.35 Million | -- |
| 1997-12-31 | $0.00 | -- |
| 1996-12-31 | $0.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Protalix Biotherapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38499700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Protalix Biotherapeutics Inc Net Assets Breakdown (December 2025)
Protalix Biotherapeutics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $80.00K | 0.17% |
| Other Components | $433.15 Million | 898.09% |
| Total Equity | $48.23 Million | 100.00% |
Protalix Biotherapeutics Inc Competitors by Market Cap
The table below lists competitors of Protalix Biotherapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Smec Co.Ltd
KQ:099440
|
$156.36 Million |
|
Angel Oak Mortgage Inc
NYSE:AOMR
|
$156.46 Million |
|
E-Life Mall Corp
TW:6281
|
$156.54 Million |
|
Plotech Co Ltd
TW:6141
|
$156.60 Million |
|
Holmes Place International Ltd
TA:HLMS
|
$156.24 Million |
|
Formuepleje Limittellus
CO:FPILIM
|
$156.21 Million |
|
Chiang Mai Ram Medical Business Public Company Limited
BK:CMR
|
$156.08 Million |
|
Emilia Devel
TA:EMDV
|
$156.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Protalix Biotherapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 43,211,000 to 48,230,000, a change of 5,019,000 (11.6%).
- Net loss of 6,604,000 reduced equity.
- Share repurchases of 9,326,000 reduced equity.
- New share issuances of 6,812,000 increased equity.
- Other factors increased equity by 14,137,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.60 Million | -13.69% |
| Share Repurchases | $9.33 Million | -19.34% |
| Share Issuances | $6.81 Million | +14.12% |
| Other Changes | $14.14 Million | +29.31% |
| Total Change | $- | 11.62% |
Book Value vs Market Value Analysis
This analysis compares Protalix Biotherapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.42x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $0.00 | $2.10 | x |
| 1997-12-31 | $0.00 | $2.10 | x |
| 1998-12-31 | $73.51 | $2.10 | x |
| 1999-12-31 | $30.45 | $2.10 | x |
| 2000-12-31 | $33.47 | $2.10 | x |
| 2001-12-31 | $29.30 | $2.10 | x |
| 2002-12-31 | $27.31 | $2.10 | x |
| 2003-12-31 | $22.48 | $2.10 | x |
| 2004-12-31 | $16.99 | $2.10 | x |
| 2005-12-31 | $28.91 | $2.10 | x |
| 2006-12-31 | $82.88 | $2.10 | x |
| 2007-12-31 | $9.48 | $2.10 | x |
| 2008-12-31 | $5.84 | $2.10 | x |
| 2009-12-31 | $2.06 | $2.10 | x |
| 2010-12-31 | $-1.40 | $2.10 | x |
| 2011-12-31 | $-3.08 | $2.10 | x |
| 2012-12-31 | $-0.37 | $2.10 | x |
| 2013-12-31 | $-2.92 | $2.10 | x |
| 2014-12-31 | $-5.99 | $2.10 | x |
| 2015-12-31 | $1.15 | $2.10 | x |
| 2016-12-31 | $-0.98 | $2.10 | x |
| 2017-12-31 | $-2.39 | $2.10 | x |
| 2018-12-31 | $-3.59 | $2.10 | x |
| 2019-12-31 | $-4.74 | $2.10 | x |
| 2020-12-31 | $-0.93 | $2.10 | x |
| 2021-12-31 | $-0.14 | $2.10 | x |
| 2022-12-31 | $-0.22 | $2.10 | x |
| 2023-12-31 | $0.41 | $2.10 | x |
| 2024-12-31 | $0.53 | $2.10 | x |
| 2025-12-31 | $0.61 | $2.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Protalix Biotherapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12.52%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 1.71x
- Recent ROE (-13.69%) is above the historical average (-20.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 0.00% | 0.00% | 0.00x | 0.00x | $131.68K |
| 1997 | 0.00% | 0.00% | 0.00x | 0.00x | $118.44K |
| 1998 | -34.19% | -14.27% | 1.68x | 1.42x | $-1.48 Million |
| 1999 | -62.82% | -28.07% | 1.74x | 1.29x | $-1.16 Million |
| 2000 | -7.89% | -10600000.00% | 0.00x | 1.42x | $-240.38K |
| 2001 | -34.78% | 0.00% | 0.00x | 1.08x | $-423.59K |
| 2002 | -18.84% | 0.00% | 0.00x | 1.10x | $-229.61K |
| 2003 | -21.47% | 0.00% | 0.00x | 1.12x | $-206.26K |
| 2004 | -32.31% | -37.23% | 0.76x | 1.14x | $-209.61K |
| 2005 | -628.37% | -3830.67% | 0.15x | 1.08x | $-5.84 Million |
| 2006 | -38.82% | -6284.67% | 0.01x | 1.11x | $-11.86 Million |
| 2007 | -35.30% | 0.00% | 0.00x | 1.07x | $-28.85 Million |
| 2008 | -50.54% | 0.00% | 0.00x | 1.15x | $-26.85 Million |
| 2009 | -197.95% | -8103.09% | 0.00x | 6.21x | $-33.03 Million |
| 2010 | 0.00% | -257.90% | 0.17x | 0.00x | $-27.87 Million |
| 2011 | 0.00% | -435.60% | 0.16x | 0.00x | $-33.92 Million |
| 2012 | 0.00% | -33.75% | 0.44x | 0.00x | $-11.28 Million |
| 2013 | 0.00% | -241.38% | 0.10x | 0.00x | $-25.10 Million |
| 2014 | 0.00% | -197.51% | 0.19x | 0.00x | $-24.38 Million |
| 2015 | 533.77% | 1329.90% | 0.04x | 8.94x | $56.95 Million |
| 2016 | 0.00% | -319.22% | 0.11x | 0.00x | $-28.37 Million |
| 2017 | 0.00% | -395.86% | 0.29x | 0.00x | $-80.31 Million |
| 2018 | 0.00% | -77.27% | 0.56x | 0.00x | $-21.17 Million |
| 2019 | 0.00% | -33.42% | 1.20x | 0.00x | $-11.24 Million |
| 2020 | 0.00% | -10.37% | 0.93x | 0.00x | $-3.82 Million |
| 2021 | 0.00% | -71.92% | 0.52x | 0.00x | $-26.98 Million |
| 2022 | 0.00% | -31.33% | 0.85x | 0.00x | $-13.86 Million |
| 2023 | 24.76% | 12.69% | 0.78x | 2.52x | $4.96 Million |
| 2024 | 6.79% | 5.49% | 0.73x | 1.70x | $-1.39 Million |
| 2025 | -13.69% | -12.52% | 0.64x | 1.71x | $-11.43 Million |
Industry Comparison
This section compares Protalix Biotherapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Protalix Biotherapeutics Inc (PLX) | $48.23 Million | 0.00% | 0.71x | $156.31 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Protalix Biotherapeutics Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also d… Read more